Feasibility and validity of the RADAI, a self‐administered rheumatoid arthritis disease activity index

Fransen, Jaap; Langenegger, Thomas; Michel, Beat A.; Stucki, Gerold

doi:10.1093/rheumatology/39.3.321

Cited by 150 publications

(127 citation statements)

References 17 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…This phase IIIb open-label trial is registered in the U.S. 11 used to assess joint involvement in psoriasis, and the EuroQoL Health Questionnaire (EQ-5D), a nondisease-specific questionnaire used to describe health outcomes. 12 The RADAI was applied only to randomized subjects with psoriatic arthritis (PsA).…”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Barker

Hoffmann²,

Wozel

et al. 2011

British Journal of Dermatology

180

121

View full text Add to dashboard Cite

Conflicts of interestSee Appendix 1. DOI 10.1111/j. 1365-2133.2011.10615.x SummaryBackground Infliximab is indicated for treatment of moderate-to-severe plaque psoriasis in adults whose disease cannot be controlled with other systemic therapies, including methotrexate (MTX). To date, no studies have directly compared the efficacy and safety of infliximab and MTX. Objectives To compare the efficacy and safety of infliximab vs. MTX in adults with moderate-to-severe plaque psoriasis. Methods MTX-naïve patients (n = 868) were randomized 3 : 1 to receive infliximab 5 mg kg )1 at weeks 0, 2, 6, 14 and 22 or MTX 15 mg weekly with a dose

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Barker

Hoffmann²,

Wozel

et al. 2011

British Journal of Dermatology

180

121

View full text Add to dashboard Cite

show abstract

“…At each assessment, demographic variables were recorded, including sex, age, ethnic origin, education level, current marital status, medical history, and total family income. Disease status and activity variables collected included the Stanford Health Assessment Questionnaire (HAQ) functional disability index (19,20), pain, global disease severity, and fatigue as recorded on visual analog scales (VAS) (21), the Arthritis Impact Measurement Scales (AIMS) anxiety and depression scales (22,23), and the Rheumatoid Arthritis Disease Activity Index (RADAI) (24)(25)(26). Patients also completed the Medical Outcomes Study Short Form 36 (SF-36), from which the physical component score (PCS) and the mental component score were calculated (27,28).…”

Section: Methodsmentioning

confidence: 99%

Direct medical costs and their predictors in patients with rheumatoid arthritis

Michaud¹,

Messer²,

Choi³

et al. 2003

Arthritis & Rheumatism

249

147

View full text Add to dashboard Cite

Objective. To estimate total direct medical costs in persons with rheumatoid arthritis (RA) and to characterize predictors of these costs.Methods. Patients (n ‫؍‬ 7,527) participating in a longitudinal study of outcome in RA completed 25,050 semiannual questionnaires from January 1999 through December 2001. From these we determined direct medical care costs converted to 2001 US dollars using the consumer price index. We used generalized estimating equations to examine potential predictors of the costs. Monte Carlo simulations and sensitivity analyses were performed to evaluate the varying prevalence and cost of biologic therapy.Results. The mean total annual direct medical care cost in 2001 for a patient with RA was $9,519. Drug costs were $6,324 (66% of the total), while hospitalization costs were only $1,573 (17%). Approximately 25% of patients received biologic therapy. The mean total annual direct cost for patients receiving biologic agents was $19,016 per year, while the cost for those not receiving biologic therapy was $6,164. RA patients who were in the worst quartile of functional status, as measured by the Health Assessment Questionnaire, experienced direct medical costs for the subsequent year that were $5,022 more than the costs incurred by those in the best quartile. Physical status as determined by the Short Form 36 physical component scale had a similar large effect on RA costs, as did comorbidity. Medical insurance type played a more limited role. However, those without insurance had substantially lower service utilization and costs, and health maintenance organization patients had lower drug costs and total medical costs. Increased years of education, increased income, and majority ethnic status were all associated with increased drug costs but not hospitalization costs. Costs in all categories decreased after age 65 years.Conclusion. Estimates of direct medical costs for patients with RA are substantially higher than cost estimates before the biologic therapy era, and costs are now driven predominantly by the cost of drugs, primarily biologic agents. RA patients with poor function continue to incur substantially higher costs, as do those with comorbid conditions, and sociodemographic characteristics also play an important role in determination of costs.

show abstract

“…Although recent advances in treatment have led to an increase in the proportion of patients reaching a state of remission 22 there is no "gold standard" measurement of disease activity and remission in RA 4 . Numerous pooled indices have been developed to measure disease activity, each of which incorporates 3-10 different assessments 23,24,25,26,27,28,29,30,31 . This in turn means that several definitions of remission, all using different criteria, have been developed.…”

Section: Assessments For Standard Clinical Carementioning

confidence: 99%

Improving the Routine Management of Rheumatoid Arthritis: The Value of Tight Control

Mease¹

2010

J Rheumatol

View full text Add to dashboard Cite

Evidence is mounting that adopting a tight control approach to the management of patients with rheumatoid arthritis (RA) yields superior clinical outcomes including inhibition of progressive structural damage. While this approach has been successfully implemented in other chronic diseases, such as diabetes, its use in RA is less straightforward as there is not a simple “gold standard” measure for disease activity. A key component of the tight control approach is the availability of easily implemented and clinically relevant assessment measures of disease activity that allow physicians to monitor progress toward preset goals. This article summarizes the evidence from clinical trials demonstrating the benefits of achieving tight control and surveys the instruments available to assess patient progress in a consistent manner. A case study clearly demonstrates the benefits of the tight control approach in routine clinical practice.

show abstract

Feasibility and validity of the RADAI, a self‐administered rheumatoid arthritis disease activity index

Abstract: The RADAI is valid to assess disease activity in RA patients. However, the RADAI may not automatically replace other measures of disease activity, such as the DAS28.

Cited by 150 publications

References 17 publications

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Direct medical costs and their predictors in patients with rheumatoid arthritis

Improving the Routine Management of Rheumatoid Arthritis: The Value of Tight Control

Contact Info

Product

Resources

About